Eli Lilly's Stock Faces High Valuation Risks
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy LLY?
Source: Fool
- Significant Growth Potential: Eli Lilly's GLP-1 treatments, Zepbound and Mounjaro, are in high demand, expected to generate billions in revenue, pushing its market cap to around $900 billion, reflecting strong market confidence.
- New Product Launch: The company plans to launch a GLP-1 weight loss pill this year, which could further enrich its product portfolio and provide new revenue growth drivers, solidifying its leadership in the global healthcare market.
- Valuation Risks: Despite Eli Lilly's stock soaring over 400% in the past five years, its current P/E ratio exceeds 40, prompting investors to be cautious about potential market share erosion due to increasing competition, which could impact stock performance.
- Short-term Volatility Expected: While Eli Lilly is viewed as a solid long-term investment, its high valuation may lead to approximately an 8% decline in stock price in the short term, necessitating careful assessment of market dynamics by investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 985.080
Low
950.00
Averages
1192
High
1500
Current: 985.080
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly's Growth Accelerates Amid High Valuation Concerns
- GLP-1 Drug Growth: Eli Lilly's GLP-1 treatments, Zepbound and Mounjaro, are in high demand, significantly boosting revenue and expected to maintain strong growth, solidifying its leadership in the global healthcare market.
- Valuation Pressure: With a market cap around $900 billion and trading at over 40 times trailing earnings, Eli Lilly's high valuation may hinder investors' ability to achieve strong returns in the future, necessitating careful risk assessment.
- New Product Launch: The company plans to launch a GLP-1 weight loss pill this year, which could add a fast-growing product to its portfolio, enhancing market competitiveness and attracting more investor interest.
- Increasing Competition: While Eli Lilly currently dominates the GLP-1 space, it may face increased competition in the future, with other healthcare companies potentially eroding its market share, making investments at such high valuations risky.
See More
Eli Lilly's Stock Faces High Valuation Risks
- Significant Growth Potential: Eli Lilly's GLP-1 treatments, Zepbound and Mounjaro, are in high demand, expected to generate billions in revenue, pushing its market cap to around $900 billion, reflecting strong market confidence.
- New Product Launch: The company plans to launch a GLP-1 weight loss pill this year, which could further enrich its product portfolio and provide new revenue growth drivers, solidifying its leadership in the global healthcare market.
- Valuation Risks: Despite Eli Lilly's stock soaring over 400% in the past five years, its current P/E ratio exceeds 40, prompting investors to be cautious about potential market share erosion due to increasing competition, which could impact stock performance.
- Short-term Volatility Expected: While Eli Lilly is viewed as a solid long-term investment, its high valuation may lead to approximately an 8% decline in stock price in the short term, necessitating careful assessment of market dynamics by investors.
See More
IWB Stock 52-Week High and Low Analysis
- Price Fluctuation Analysis: IWB's 52-week low is $264.17 per share, with a high of $382.34, and the latest trade at $367.38 indicates significant price movement within this range, aiding investors in assessing the current market position.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides valuable insights for technical analysis, helping investors determine price trends and potential buy or sell opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding focuses on those experiencing notable inflows (new units created) or outflows (old units destroyed), assessing their impact on underlying assets and market trends.
See More
Novo Nordisk and Hims & Hers Reach New Agreement
- Agreement Reached: Novo Nordisk and Hims & Hers Health have finalized a deal allowing Hims & Hers to sell Novo's GLP-1 drugs, Ozempic and Wegovy, including the newly approved Wegovy pill, which provides Hims & Hers with a legitimate sales channel and enhances its market competitiveness.
- Market Opportunity Improvement: Previously, Hims & Hers was selling compounded versions of these drugs under FDA scrutiny, but the new agreement enables them to sell FDA-approved medications, thus mitigating potential market risks and addressing the growing demand for GLP-1 drugs.
- Sales Outlook for Novo Nordisk: Facing intensified competition, Novo Nordisk has lowered its sales guidance for the upcoming year; however, the partnership with Hims & Hers could enhance its growth rate, particularly in protecting its market share against competitors like Eli Lilly.
- Investment Risk Assessment: While Hims & Hers has seen a stock price rebound due to the agreement, its market cap is only around $6 billion, indicating higher risk; in contrast, Novo Nordisk, valued at nearly $170 billion, despite slowing growth, remains a more stable investment option for the long term.
See More
Novo Nordisk Reaches Agreement with Hims & Hers Health
- Lawsuit Withdrawal: Novo Nordisk has decided to drop its lawsuit against Hims & Hers Health, reaching an agreement that allows Hims & Hers to sell FDA-approved Ozempic and Wegovy, thereby eliminating legal risks for Hims & Hers and enhancing its market competitiveness.
- Sales Growth Potential: By selling FDA-approved GLP-1 drugs, Hims & Hers Health can meet the increasing market demand, which is expected to significantly boost its sales performance, especially against the backdrop of surging demand for GLP-1 medications.
- Market Competition Pressure: Novo Nordisk is facing pressure from competitors like Eli Lilly and has lowered its future sales guidance; however, the partnership with Hims & Hers could improve its growth rate, helping it regain momentum in a highly competitive market.
- Market Reaction: Although shares of both Novo Nordisk and Hims & Hers fell over 20% at the start of trading, Hims & Hers experienced a significant rebound due to the agreement, indicating a positive market response to the collaboration, despite its market cap being only around $6 billion, which poses higher risks.
See More
Eli Lilly Reports Positive Phase 3 Results for EBGLYSS in Pediatric Atopic Dermatitis
- Successful Clinical Trial: Eli Lilly's Phase 3 ADorable-1 trial demonstrated that EBGLYSS met primary and key secondary endpoints at Week 16, with 63% of patients achieving significant skin improvement and 44% achieving clear or almost clear skin, indicating the drug's efficacy in treating moderate-to-severe atopic dermatitis in children.
- Widespread Disease Impact: Atopic dermatitis affects 9.6 million children in the U.S., with one-third suffering from moderate-to-severe cases, and the success of EBGLYSS offers new treatment hope for this large patient population, potentially improving their quality of life significantly.
- Good Safety Profile: The safety and tolerability of EBGLYSS were consistent with adult and adolescent studies, with no injection site pain reported, indicating a high safety profile for use in pediatric patients and enhancing its market potential.
- Positive Market Reaction: In pre-market trading on Monday, Eli Lilly's stock was priced at $986.37, up 0.11%, reflecting investor optimism regarding the positive clinical results of EBGLYSS, which may drive future growth for the company.
See More
Eli Lilly's Growth Accelerates Amid High Valuation Concerns
- GLP-1 Drug Growth: Eli Lilly's GLP-1 treatments, Zepbound and Mounjaro, are in high demand, significantly boosting revenue and expected to maintain strong growth, solidifying its leadership in the global healthcare market.
- Valuation Pressure: With a market cap around $900 billion and trading at over 40 times trailing earnings, Eli Lilly's high valuation may hinder investors' ability to achieve strong returns in the future, necessitating careful risk assessment.
- New Product Launch: The company plans to launch a GLP-1 weight loss pill this year, which could add a fast-growing product to its portfolio, enhancing market competitiveness and attracting more investor interest.
- Increasing Competition: While Eli Lilly currently dominates the GLP-1 space, it may face increased competition in the future, with other healthcare companies potentially eroding its market share, making investments at such high valuations risky.
See More
Eli Lilly's Stock Faces High Valuation Risks
- Significant Growth Potential: Eli Lilly's GLP-1 treatments, Zepbound and Mounjaro, are in high demand, expected to generate billions in revenue, pushing its market cap to around $900 billion, reflecting strong market confidence.
- New Product Launch: The company plans to launch a GLP-1 weight loss pill this year, which could further enrich its product portfolio and provide new revenue growth drivers, solidifying its leadership in the global healthcare market.
- Valuation Risks: Despite Eli Lilly's stock soaring over 400% in the past five years, its current P/E ratio exceeds 40, prompting investors to be cautious about potential market share erosion due to increasing competition, which could impact stock performance.
- Short-term Volatility Expected: While Eli Lilly is viewed as a solid long-term investment, its high valuation may lead to approximately an 8% decline in stock price in the short term, necessitating careful assessment of market dynamics by investors.
See More
IWB Stock 52-Week High and Low Analysis
- Price Fluctuation Analysis: IWB's 52-week low is $264.17 per share, with a high of $382.34, and the latest trade at $367.38 indicates significant price movement within this range, aiding investors in assessing the current market position.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides valuable insights for technical analysis, helping investors determine price trends and potential buy or sell opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding focuses on those experiencing notable inflows (new units created) or outflows (old units destroyed), assessing their impact on underlying assets and market trends.
See More
Novo Nordisk and Hims & Hers Reach New Agreement
- Agreement Reached: Novo Nordisk and Hims & Hers Health have finalized a deal allowing Hims & Hers to sell Novo's GLP-1 drugs, Ozempic and Wegovy, including the newly approved Wegovy pill, which provides Hims & Hers with a legitimate sales channel and enhances its market competitiveness.
- Market Opportunity Improvement: Previously, Hims & Hers was selling compounded versions of these drugs under FDA scrutiny, but the new agreement enables them to sell FDA-approved medications, thus mitigating potential market risks and addressing the growing demand for GLP-1 drugs.
- Sales Outlook for Novo Nordisk: Facing intensified competition, Novo Nordisk has lowered its sales guidance for the upcoming year; however, the partnership with Hims & Hers could enhance its growth rate, particularly in protecting its market share against competitors like Eli Lilly.
- Investment Risk Assessment: While Hims & Hers has seen a stock price rebound due to the agreement, its market cap is only around $6 billion, indicating higher risk; in contrast, Novo Nordisk, valued at nearly $170 billion, despite slowing growth, remains a more stable investment option for the long term.
See More
Novo Nordisk Reaches Agreement with Hims & Hers Health
- Lawsuit Withdrawal: Novo Nordisk has decided to drop its lawsuit against Hims & Hers Health, reaching an agreement that allows Hims & Hers to sell FDA-approved Ozempic and Wegovy, thereby eliminating legal risks for Hims & Hers and enhancing its market competitiveness.
- Sales Growth Potential: By selling FDA-approved GLP-1 drugs, Hims & Hers Health can meet the increasing market demand, which is expected to significantly boost its sales performance, especially against the backdrop of surging demand for GLP-1 medications.
- Market Competition Pressure: Novo Nordisk is facing pressure from competitors like Eli Lilly and has lowered its future sales guidance; however, the partnership with Hims & Hers could improve its growth rate, helping it regain momentum in a highly competitive market.
- Market Reaction: Although shares of both Novo Nordisk and Hims & Hers fell over 20% at the start of trading, Hims & Hers experienced a significant rebound due to the agreement, indicating a positive market response to the collaboration, despite its market cap being only around $6 billion, which poses higher risks.
See More
Eli Lilly Reports Positive Phase 3 Results for EBGLYSS in Pediatric Atopic Dermatitis
- Successful Clinical Trial: Eli Lilly's Phase 3 ADorable-1 trial demonstrated that EBGLYSS met primary and key secondary endpoints at Week 16, with 63% of patients achieving significant skin improvement and 44% achieving clear or almost clear skin, indicating the drug's efficacy in treating moderate-to-severe atopic dermatitis in children.
- Widespread Disease Impact: Atopic dermatitis affects 9.6 million children in the U.S., with one-third suffering from moderate-to-severe cases, and the success of EBGLYSS offers new treatment hope for this large patient population, potentially improving their quality of life significantly.
- Good Safety Profile: The safety and tolerability of EBGLYSS were consistent with adult and adolescent studies, with no injection site pain reported, indicating a high safety profile for use in pediatric patients and enhancing its market potential.
- Positive Market Reaction: In pre-market trading on Monday, Eli Lilly's stock was priced at $986.37, up 0.11%, reflecting investor optimism regarding the positive clinical results of EBGLYSS, which may drive future growth for the company.
See More
